Why the study?
What are the pharmacokinetic properties of intravenous ouabain in dogs and humans?
What are the pharmacokinetic properties of intravenous ouabain in dogs and humans?
The pharmacokinetic half-life of intravenous ouabain is approximately 21 hours in humans, correlating well with its clinical duration of action.
Answers are grounded in this paper and cite their sources.
Informs potential ouabain dosing intervals in humans; extends canine PK data yet leaves open validation in patients.
The pharmacokinetics of the relatively polar and rapidly acting cardiac glycoside ouabain (G-strophanthin) were studied in dogs and human subjects by the use of a newly devised radioimmunoassay technic. This method had high specificity and a sensitivity of less than 0.1 ng of ouabain per ml of plasma or urine. After administration of a single intravenous dose, the plasma ouabain concentration fell rapidly in both dogs and humans. After 7 hours, a phase of exponential decline was reached which had a half-life of 18 hours in dogs and 21 hours in normal human subjects. Repeated intravenous administration of ouabain to human subjects for 9 consecutive days resulted in the establishment of a plateau of plasma concentration and urinary excretion after 4-5 days, confirming plasma and urinary half-lives in the 19-24-hour range. The mean ratio of renal clearance of ouabain to that of creatinine was 0.81 in the human subjects. The plasma half-life of ouabain determined in these studies is in good agreement with previous observations of the half-life of dissipation of positive inotropy and of slowing of ventricular response to atrial fibrillation after ouabain administration.
No takes yet. Share an insight, caveat, or question.
Selden et al. (1972) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: